A treatment option for adults with relapsed or refractory multiple myeloma who have received at least four treatment regimens, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody to treat their multilple myeloma, and their cancer has come back or did not respond to prior treatment. TECVAYLITM is approved based on patient response. Data are not yet available to show if TECVAYLITM improves survival or symptoms.
It is not known if TECVAYLITM is safe and effective in children.
Sign up now to stay informed about the latest updates on TECVAYLI™. Ask your doctor if TECVAYLI™ may be right for you.
Download this brochure to review the Medication Guide and additional information about getting started with TECVAYLI™.
Get the GuideSign up for the latest information about TECVAYLI™
Janssen Biotech, Inc., our affiliates, and our service providers will use the information that you provide to send you personalized communications about TECVAYLI™ and relapsed or refractory multiple myeloma and your optional requests, and to research, develop, and improve our products and services. Please note that the subject line of email messages that you receive may include TECVAYLI™ or relapsed or refractory multiple myeloma. You may unsubscribe from these communications by following the instructions in them. Our Privacy Policy further governs the use of the information you provide.